Evidence map›Paper›PMID 39850811›Full record

ArticleFrontiers in oncology2024

Distinct mRNA expression profiles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets.

Tomasz Sirek, Katarzyna Król-Jatręga, Przemysław Borawski, Nikola Zmarzły, Dariusz Boroń, Piotr Ossowski, Olga Nowotny-Czupryna, Kacper Boroń, Dominika Janiszewska-Bil, Elżbieta Mitka-Krysiak and 1 more

Erratum issuedAbstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Exploring the therapeutic potential andFrontiers in pharmacology · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Tomasz SirekDepartment of Plastic Surgery, Faculty of Medicine, Academia of Silesia, Katowice, Poland.
Katarzyna Król-JatręgaDepartment of Plastic Surgery, Faculty of Medicine, Academia of Silesia, Katowice, Poland.
Przemysław BorawskiIndependent Researcher, Włocławek, Poland.
Nikola ZmarzłyDepartment of Medical and Health Sciences, Collegium Medicum, WSB University, Dabrowa Górnicza, Poland.
Dariusz BorońDepartment of Medical and Health Sciences, Collegium Medicum, WSB University, Dabrowa Górnicza, Poland.
Piotr OssowskiDepartment of Medical and Health Sciences, Collegium Medicum, WSB University, Dabrowa Górnicza, Poland.
Olga Nowotny-CzuprynaDepartment of Medical and Health Sciences, Collegium Medicum, WSB University, Dabrowa Górnicza, Poland.
Kacper BorońDepartment of Plastic Surgery, Faculty of Medicine, Academia of Silesia, Katowice, Poland.
Dominika Janiszewska-BilDepartment of Medical and Health Sciences, Collegium Medicum, WSB University, Dabrowa Górnicza, Poland.
Elżbieta Mitka-KrysiakDepartment of Medical and Health Sciences, Collegium Medicum, WSB University, Dabrowa Górnicza, Poland.
Beniamin Oskar GrabarekDepartment of Medical and Health Sciences, Collegium Medicum, WSB University, Dabrowa Górnicza, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Breast cancer remains a leading cause of mortality among women, driven by the molecular complexity of its various subtypes. This study aimed to investigate the differential expression of genes and miRNAs involved in the PI3K/AKT/mTOR signaling pathway, a critical regulator of cancer progression. Methods: We analyzed tumor tissues from five breast cancer subtypes-luminal A, luminal B HER2-negative, luminal B HER2-positive, HER2-positive, and triple-negative breast cancer (TNBC)-and compared them with non-cancerous tissues. Microarray and qRT-PCR techniques were employed to profile mRNAs and miRNAs, while bioinformatic tools predicted miRNA-mRNA interactions. Statistical analysis was performed with a statistical significance threshold (p) < 0.05. Results: We identified several upregulated genes across all subtypes, with TNBC and HER2-positive cancers showing the most significant changes. Key genes such as Conclusion: Our findings suggest that the PI3K/AKT/mTOR pathway and its miRNA regulators play crucial roles in breast cancer progression, particularly in aggressive subtypes like TNBC. The identified miRNAs and mRNAs hold potential as biomarkers for diagnosis and treatment, but further validation in functional studies is required. This study provides a foundation for targeted therapies aimed at modulating this critical pathway to improve breast cancer outcomes.

Indexed as

breast cancermiRNAmolecular markermRNAPI3K/Akt/mTOR pathway

Identifiers

PMID39850811
PMCPMC11754234

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.